NCT04470674View on ClinicalTrials.gov

Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (≥ 50%) NSCLC Patients

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

April 6, 2021

Primary Completion Date

June 8, 2021

Study Completion Date

June 8, 2021

Conditions
Lung CancerNon-small Cell Lung CancerPD-L1 Gene MutationKRAS Activating Mutation
Interventions
DRUG

Durvalumab

Durvalumab 1500 mg

DRUG

Carboplatin

carboplatin AUC 5

DRUG

Pemetrexed

pemetrexed 500 mg/m2

Trial Locations (1)

48202

Henry Ford Health System, Detroit

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

collaborator

Henry Ford Health System

OTHER

lead

Shirish M Gadgeel

OTHER